Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CPA1 | P15085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27032963 | 1.00 | TDP1 (0.39) | TDP1CTSLCTSBCTSSCTSK | |
| SCHEMBL30564475 | 0.81 | TSHR (0.38) | TDP1TSHRCYP3A4 | |
| SCHEMBL27032786 | 0.81 | MMP2 (0.46) | CTSLCTSBCTSSCTSKRNPEP | |
| SCHEMBL27145013 | 0.81 | MMP2 (0.46) | CTSLCTSBCTSSCTSKRNPEP | |
| SCHEMBL30639539 | 0.81 | MMP2 (0.46) | CTSLCTSBCTSSCTSKRNPEP | |
| SCHEMBL28894252 | 0.80 | TDP1 (0.39) | TDP1TSHRCYP3A4 | |
| SCHEMBL31678050 | 0.80 | CTSL (0.33) | TDP1CTSLCTSBCTSSCTSK | |
| SCHEMBL2969773 | 0.76 | ITGB3 (0.45) | NPSR1CYP3A4 | |
| SCHEMBL6130393 | 0.76 | ITGB3 (0.45) | NPSR1CYP3A4 | |
| SCHEMBL7375873 | 0.75 | ALDH1A1 (0.39) | CTSLCTSBCTSSCTSKTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268979-A1 | COMBINATION OF MACROCYCLIC CFTR MODULATORS WITH CFTR CORRECTORS AND / OR CFTR POTENTIATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-08-28 | — | — | US | disclosed |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-27 | — | — | US | disclosed |
| EP-4308575-A1 | MACROCYCLES AS CFTR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2024-01-24 | — | — | EP | disclosed |
| CN-116981672-A | Macrocyclic compounds as CFTR modulators | 爱杜西亚药品有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2022194399-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268979-A1 | COMBINATION OF MACROCYCLIC CFTR MODULATORS WITH CFTR CORRECTORS AND / OR CFTR POTENTIATORS | CFTR, RRS1, PKD1 | TDP1 3748/4885CTSL 2425/4885CTSB 2783/4885 |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | CFTR, PKD1, ARRB1 | TDP1 4270/4885CTSL 4121/4885CTSB 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.